Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
Multiple sclerosis (MS) powerhouse Biogen Japan will spin off its growing hemophilia business into a new entity, with its operational launch slated for “the first part of 2017,” President Steve Sugino said in an interview with Jiho on September 7.…
To read the full story
Related Article
- Bioverativ Japan Launched on Feb. 1
February 3, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…